China Money Network
Login
Join

V-Capital Leads $25M New Round In Ocular Drug Developer Cloudbreak Therapeutics

  • April 17, 2020 — 16:30 CST

This Data Is Locked!

This area is available only to Subscribers.

Cloudbreak Therapeutics, a Chinese clinical-stage biotechnology company focusing on ocular drug development, has recently completed a Series B round of fundraising at RMB180 million (US$25.4... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: